title: 2-(fluorine-18)-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography after breast conserving surgery: Correlation with molecular markers of breast cancer.
abstract: OBJECTIVE
  To investigate the role of 2-(fluorine-18)-fluoro-2-deoxy-D-glucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) early after breast-conserving surgery (BCS) in patients with breast cancer (BC) and whether we can determine which molecular biomarkers of breast carcinoma put the patients at risk.
  
  
  METHODS
  This retrospective study involved 88 patients with histologically proven T1 or T2 BC, who were treated with BCS and underwent (18)F-FDG PET/CT study. The correlation between biological markers (estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 [HER2], and Ki-67) of the primary tumor and (18)F-FDG PET/CT findings was analyzed.
  
  
  RESULTS
  (18)F-FDG PET/CT demonstrated the presence of BC disease (locoregional disease [LRD], distant metastases, or contralateral BC) in 26 of 88 patients (29.5%). Regarding immunohistochemical profiles, BC expressing high levels of Ki-67 were associated with an increased percentage of LRD, which was the major recurrence pattern on (18)F-FDG PET/CT. Although the BC disease was observed more commonly in patients with HER2 positivity compared to those of HER2 negative, the difference did not reach statistical significance. The patients with T2 tumor or a higher histopathological grade had a higher percentage of BC disease.
  
  
  CONCLUSIONS
  This study demonstrated that patients with early stage BC treated with BCS have a remarkable risk of the presence of BC even early after surgery, and there was a clinically important relationship between (18)F-FDG PET/CT findings and biological markers of BC. These findings suggest that high-risk molecular biomarkers (Ki-67, HER2) can be taken into account in the decision-making the process for both preoperative imaging and planning of the surgical approach.
authors.affiliation: Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey.
authors.forename: Salih
authors.initials: S
authors.lastname: Ozguven
authors.affiliation: Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey.
authors.forename: Sabahat
authors.initials: S
authors.lastname: Inanir
authors.affiliation: Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey.
authors.forename: Halil Turgut
authors.initials: HT
authors.lastname: Turoglu
authors.affiliation: Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey.
authors.forename: Tanju Yusuf
authors.initials: TY
authors.lastname: Erdil
authors.affiliation: Department of General Surgery, Marmara University School of Medicine, Istanbul, Turkey.
authors.forename: Mustafa Umit
authors.initials: MU
authors.lastname: Ugurlu
authors.affiliation: Department of General Surgery, Marmara University School of Medicine, Istanbul, Turkey.
authors.forename: Bahadir
authors.initials: B
authors.lastname: Gulluoglu
keywords: Breast neoplasms; Ki-67 antigen; fluorodeoxyglucose F18; human epidermal growth factor receptor 2; mastectomy; positron emission tomography; segmental